Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States (13% of 2024 revenues), diagnostic products (20% of 2024 revenues), nutritional products (22% of 2024 revenues), and medical devices (45% of 2024 revenues).[2]
Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide.[2]
Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip.[2]
The company is ranked 107th on the Fortune 500[3] and 144th on the Forbes Global 2000.[4]
History
Foundation and early history
In 1888 at the age of 30, Wallace Abbott (1857–1921), an 1885 graduate of the University of Michigan, founded the Abbott Alkaloidal Company in Ravenswood, Chicago. At the time, he was a practising physician and owned a drug store. His innovation was formulating the active part of alkaloid medicinal plants—morphine, quinine, strychnine and codeine—as tiny "dosimetric granules", producing more consistent and effective dosages for patients than the liquid preparations previously used, which deteriorated over time.[5] In 1922, the company moved from Ravenswood to North Chicago, Illinois.
International expansion
Abbott's first international affiliate was in London in 1907; the company later added an affiliate in Montreal, Canada. Abbott India Ltd was originally incorporated on August 22, 1944, as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, and to Boots Pharmaceuticals Ltd on January 1, 1991. On October 31, 1995, the name was changed to Knoll Pharmaceuticals Ltd and on July 1, 2002, to its present name Abbott India Ltd. Abbott started operations in Pakistan as a marketing affiliate in 1948; the company has steadily expanded to comprise a work force of over 1500 employees. Currently, two manufacturing facilities at Landhi and Korangi in Karachi continue to produce pharmaceutical products.[6] In 1962, Abbott entered into a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radio-pharmaceuticals. In 1964, it merged with Ross Laboratories, making Ross a wholly owned subsidiary of Abbott, and Richard Ross gained a seat on Abbott's board of directors until his retirement in 1983.[7] The acquisition of Ross brought Similac under the Abbott umbrella. In the years following the acquisition, Pedialyte and Ensure were introduced as nutritional products by Ross Laboratories while under Abbott's leadership.[8][9][10]
In 1965, Abbott's expansion in Europe continued with offices in Italy and France.
According to Harvard professor Lester Grinspoon and Peter Hedblom, "In 1966 Abbott Laboratories sold the equivalent of two million doses of methamphetamine in powder form to a Long Island criminal dealer".[11]
In 1985, Abbott partnered with Taisho Pharmaceutical for the international rights to clarithromycin, a second-generation macrolide antibiotic, and gained FDA approval for the drug under the brand name Biaxin in October 1991. Generic drug versions were approved in Europe in 2004 and in the US in mid-2005,[12] and has been added to the World Health Organization's List of Essential Medicines.[13]
2001–2010
In 2001, the company acquired Knoll, the pharmaceutical division of BASF, for $6.9 billion.[14] In 2002, it divested the Selsun Blue brand to Chattem.[15] Later in 2002, it sold Clear Eyes and Murine brands to Prestige Brands.[16]
In 2004, Abbott completed the corporate spin-off of Hospira, its hospital products division.[17] It was acquired by Pfizer in 2015.[18]
In 2004, it acquired TheraSense, a diabetes-care company, which it merged with its MediSense division to become Abbott Diabetes Care.[19] In 2006, Abbott assisted Boston Scientific in its purchase of Guidant Corporation purchasing the vascular device division of Guidant.[20][21]
In 2007, Abbott acquired Kos Pharmaceuticals for $3.7 billion in cash.[22] At the time of acquisition Kos marketed Niaspan (extended release niacin), and Advicor (niacin/lovastatin).
In 2007, the company was to sell two diagnostics divisions to General Electric, but the parties did not agree on the terms of the acquisition.[23]
On 8 September 2007, the company sold the UK manufacturing plant at Queenborough to UK manufacturer Aesica Pharmaceuticals.[24][25]
Abbott's Ross Products was renamed Abbott Nutrition in 2007.[26]
In 2009, Abbott acquired Advanced Medical Optics of Santa Ana, California, selling it to Johnson & Johnson in 2017.[27] In 2009, Abbott opened a satellite research and development facility at Research Park, University of Illinois at Urbana-Champaign.[28]
In February 2010, Abbott acquired the pharmaceuticals unit of Solvay S.A. for US$6.2 billion (€4.5 billion),[29] gaining many additional pharmaceutical products and an increased presence in emerging markets.[30]
In 2010, the company acquired Hollywood, Florida-based laboratory information management system company STARLIMS for $123 million, $14 per share.[31][32] That year Abbott said it would buy Piramal Group of India's large generic drugs unit for $3.72 billion.[33]
2013–present
Effective January 1, 2013, the company completed the corporate spin-off of AbbVie.[34][35][36][37][38] Abbott Nutrition, whose products include Similac, Pedialyte, Glucerna, and Ensure, also retained the Abbott name.[37] In preparation for the reorganization, Abbott cut 550 staff members.[39]
In May 2014, it was announced that Abbott would acquire the holding company Kalo Pharma Internacional S.L. for $2.9 billion in order to secure the 73% it held of Chilean pharmaceutical company, CFR Pharmaceuticals, which the company said would more than double its branded generic drug portfolio.[40][41]
In December 2014, the company acquired Russian pharmaceutical manufacturer Veropharm (Voronezh) in a deal worth $410 million, which included three manufacturing facilities.[42] Abbott, which already employed 1,400 people in Russia, said it planned to set up a manufacturing presence in the country when the deal closed.[43]
In September 2015, the company acquired Tendyne Holdings, a private medical device company focused on developing minimally invasive mitral valve replacement therapies, for $250 million.[44][45]
In September 2017, the FDA approved Abbott's FreeStyle Libre glucose monitoring system, which reads glucose levels through a self-applied sensor without finger pricks.[46]
In October 2017, the company acquired Alere for $5.8 billion.[47][48] In January 2017, Abbott announced it would acquire St. Jude Medical for $25 billion in stock.[49][50][51] With the acquisition of Alere, the company also obtained the subsidiary Arriva Medical, which at one point was the largest mail-order diabetic supplier.[52] Arriva Medical closed facilities in December 2017.[53]
As of August 2018, the company was among the top five companies for branded generic drugs in Russia.[54]
In November 2018, Abbott received United States FDA clearance for FreeStyle LibreLink, a glucose reader smartphone app.[55]
In January 2019, the company acquired Cephea Valve Technologies, which is developing a less-invasive replacement heart valve for people with mitral valve disease.[56]
In January 2020, the Tendyne Mitral Valve became the world's first commercially available solution for Mitral Valve Replacement Technology; with CE Mark for the device, it is possible to implant it in Europe outside of a clinical setting.[57]
In March 2020, Abbott received emergency use authorization (EUA) from the US FDA for a SARS-CoV-2 test during the COVID-19 pandemic.[58] The tester is small (comparable to a small toaster), and produces results within 13 minutes.[59] Detroit received these tests on April 1, 2020.[60][61] Also in March, the firm received EUA for a molecular COVID-19 test that runs on its m2000 RealTime lab-based platform.[62] In April 2020, itt received EUA from the FDA for its third COVID-19 test, an antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's ARCHITECT laboratory instruments.[63] In May 2020, it received EUA from the FDA for another lab-based COVID-19 antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's Alinity i system.[63][64] Also in May, it received EUA from the FDA for a molecular COVID-19 test for use on the company's Alinity molecular laboratory instrument.[65][66]
In August 2020, Abbott received EUA from the FDA for its credit-card-sized $5, 15-minute, portable COVID-19 antigen test, BinaxNOW, compatible with the NAVICA mobile app.[67][68]
In October 2020, Abbott received EUA from the FDA for its lab-based COVID-19 IgM antibody blood test.[69] In December 2020, its rapid (20') antigen BinaxNOW COVID-19 test received EUA from the FDA for home use.[70][71] Forbes reported in January 2021 that the firm had delivered more than 400 million COVID-19 tests, 300 million in the fourth quarter of 2020.[72]
In September 2021, Abbott acquired Walk Vascular, LLC.[73]
In January 2022, Abbott introduced Lingo, a line of consumer biowearable sensors that collects a range of biological readings to optimize exercise and nutrition regimens.[74]
Following the 2022 Russian invasion of Ukraine, Abbott Laboratories continued its business operations in Russia while suspending non-essential activities such as new investments and advertising.[75] Research from Yale School of Management evaluating corporate responses to the invasion placed Abbott in the "Buying Time" category with a "Grade D" rating, indicating that it postponed future investments and marketing while continuing substantive business in Russia.[76]
In May 2022, Abbott received 510(k) clearance from the FDA for FreeStyle Libre 3, the latest version of its continuous glucose monitor.[77]
In August 2022, Abbott received FDA approval for Proclaim Plus, a multi-use spinal cord stimulation system designed to target chronic pain. The Proclaim Plus system is capable of treating six independent pain sites and has a recharge-free battery life of up to 10 years.[78]
In October 2022, Abbott received EUA from the FDA for its real-time PCR test Alinity m MPXV; this marks the first FDA emergency authorization for commercial monkeypox testing.[79]
In April 2023, the company acquired Cardiovascular Systems, developer of an atherectomy system, which is used in treating peripheral and coronary artery disease, for $851 million.[80]
On July 5, 2023, Abbott received approval from the FDA for its leadless pacemaker system Aveir DR.
In September 2023, the company acquired Bigfoot Biomedical, a developer of smart insulin management systems for people with diabetes.[81][82]
In November 2025, Abbott announced an agreement to acquire Exact Sciences Corp. in a deal worth roughly $21 billion.[83]
Acquisition history
- Abbott Laboratories (Est. 1885, Abbott Alkaloidal Company)
- Ross Laboratories (Acq 1964)
- SmithKline Beecham (Acq 1982, later sold)
- Knoll (Acq 2001)
- Selsun Blue (Sold to Chattem 2002)
- Murine (Sold to Prestige Brands 2002)
- Clear Eyes (Sold to Prestige Brands 2002)
- i-STAT (Acq 2004)
- TheraSense (Acq 2004)
- Guidant (vascular device division) (Acq 2006)
- IntraLase Corp (Acq 2007)
- Advanced Medical Optics (Acq 2009)
- Solvay Pharmaceuticals (Acq 2010)
- STARLIMS (Acq 2010)
- Lab Data Management Ltd (Acq 2008)
- IDEV Technologies (Acq 2013)
- OptiMedica Corporation (Acq 2013)
- Veropharm (Acq 2014)
- Topera, Inc (Acq 2014)
- Kalo Pharma Internacional S.L. (Acq 2014)
- CFR Pharmaceuticals
- Tendyne Holdings Inc. (Acq 2015)
- Alere (Acq 2016)
- Epocal, Inc. (Acq 2013)
- Arriva Medical (Acq 2012)
- St. Jude Medical (Est 1976, Acq 2016)
- Pacesetter, Inc. (Acq 1994)
- Daig Corporation (Acq 1996)
- Heart Valve Company (Acq 1996)
- Biocor Industria (Acq 1996)
- Ventritex (Acq 1997)
- Tyco International (Angio-Seal division) (Acq 1999)
- Endocardial Solutions (Acq 2005)
- Advanced Neuromodulation Systems (Acq 2005)
- MediGuide (Acq 2008)
- AGA Medical (Acq 2010)
- LightLab Imaging (Acq 2010)
- Nanostim Inc (Acq 2013)
- Endosense (Acq 2013)
- CardioMEMS Inc. (Acq 2014)
- Spinal Modulation (Acq 2015)
- Thoratec Corporation (Acq 2015)
- Apica Cardiovascular Limited (Acq 2014)
- Levitronix (Medical division) (Acq 2011)
- Getinge Group (Heat pump technology division) (Acq 2014)
- Thermo Cardiosystems (Acq 2010)
- Cephea Valve Technologies, Inc. (Acq 2019)
- Walk Vascular, LLC (Acq 2021)
- Cardiovascular Systems, Inc. (Acq 2023)
- Bigfoot Biomedical (Acq 2023)
- Exact Sciences Corporation (Acq 2026)
Financials
Operations
Organization
Abbott's core businesses focus on diagnostics, medical devices, branded generic medicines and nutritional products, which have been supplemented through acquisitions.[2]
The firm's divisions are:[2]
- Nutrition: Pediatric nutrition (e.g., Similac, Isomil, and Gain), Adult Nutrition (e.g., Ensure and ZonePerfect) and special dietary needs (e.g., Glucerna and Juven)
- Diagnostics: core lab, molecular, point of care, rapid diagnostics and Informatics
- Medical devices: rhythm management, electrophysiology, heart failure, structural heart, neuromodulation, diabetes care
- Established Pharmaceuticals: branded generic drugs sold exclusively in developing markets
Management
Miles D. White joined the company in 1984, holding positions including senior vice president of diagnostic operations, executive vice president, executive chairman, and CEO.[39] In 1996, Robert B. Ford joined Abbott, holding various positions including executive vice president of the company's medical device business.[84]
In November 2019, White announced that he was stepping down as CEO after 21 years.[84] In March 2020, Robert B. Ford took over as president and CEO,[85] and later chairman.[86]
Recognition
- Named one of its Top 50 World's Most Admired Companies in 2021 by Fortune.[87]
- Named among the Blue ribbon companies in 2021 by Fortune.[88]
- Named to the Change the World list in 2020 by Fortune.[89]
- Ranked #10 on Most Innovative Companies in Sports for Libre Sense by Fast Company.[90]
- Received an Honorable Mention for the World Changing Ideas Awards by Fast Company in 2022.[91]
- The Galien Foundation named Abbott’s FreeStyle Libre as Best Medical Technology within the last 50 years (1970–2020).[92]
- The company has been listed on the Seramount/Working Mother's "100 Best Companies" list for 21 years in a row, named a top company for executive women by Seramount.[93][94][95]
- Included on Science magazine's Top 20 Employers list.[96]
- Recognized as a top company by DiversityInc for diversity within the company for 19 consecutive years (2004–2022).[97]
- Included on the Dow Jones Sustainability Index for 18 consecutive years.[98]
Products
Nutrition
Pediatric nutrition products manufactured by Abbott Laboratories include:[2]
Adult nutrition products manufactured by Abbott Laboratories include:
- Similac
- Similac Gain
- Similac GainPlus
- Similac GainSchool
- Similac Neosure
- Similac Essencia
- Similac Tummicare HW
- Isomil
- Pedialyte
- PediaSure
- PediaSure Plus
- PediaSure Plus 10+
- Ensure
- Ensure Gold
- Glucerna (Ensure Diabetes Care in India)
- Juven
- ZonePerfect
Diagnostics
Diagnostics products manufactured by Abbott include:[2]
Medical devices
Continuous glucose monitors:
Cardiovascular devices manufactured by Abbott Laboratories include:[2]
Neuromodulation devices manufactured by Abbott Laboratories include:
- FreeStyle Libre
- FreeStyle Libre 2 Sensor
- FreeStyle Libre 3 Sensor[101]
- MitraClip
- Confirm Rx
- Amplatzer Piccolo Occluder
- Heartmate
- Xience
- CARDIOMEMS
- Gallant ICD
- CentriMag
- Aveir DR[102]
- BurstDR Technology
- FlexBurst360 Technology
- Proclaim DRG Neurostimulation System
- Infinity Deep Brain Stimulation System
- Proclaim XR Recharge-Free Spinal Cord Stimulator
- NT2000IX Radiofrequency Generator
- Proclaim Elite Recharge-Free SCS System
- Prodigy MRI SCS System
Litigation and controversies
Use of double Irish arrangement and single malt tax to reduce taxation
Before it was abolished, Abbott allegedly took advantage of the double Irish arrangement tax structure, a then-legal but controversial Irish taxation tool used by US multinationals to reduce US corporate taxes on non-U.S profits. Abbott's Irish holding company, the Bermuda-resident Abbott Laboratories Vascular Enterprises (ALVE), employed no staff in 2017, but was responsible for distributing Abbot's products and licensing its technology worldwide. ALVE was incorporated in 2003 and had a pre-tax profit of €2 billion in 2016 and 2017 on revenues of €5.2 billion; no taxation was paid on these profits. ALVE had never filed accounts in Ireland since 2003 as it was structured as an unlimited liability company (ULC); however, new EU accounts directives required ALVE to file Irish accounts in 2018. These accounts listed ALVE's registered office as the address of Ireland's largest tax-law firm, Matheson, who have been identified with Double Irish tax structures for Microsoft and Google.[103][104]
In September 2021, the Irish Times reported that Abbott was using the Single malt tax structure to shield profits on its COVID-19 testing kits.[105][106]
Leuprorelin
In October 2001, the US Department of Justice, states attorneys general, and TAP Pharmaceutical Products, a subsidiary of Abbott Laboratories, settled criminal and civil charges against TAP related to federal and state Medicare fraud and illegal marketing of the drug leuprorelin.[107] TAP paid a total of $875 million, a record high pharmaceutical settlement.[108][109] This comprised $290 million for violating the Prescription Drug Marketing Act, $559.5 million to settle federal fraud charges for overcharging Medicare, and $25.5 million reimbursement to 50 states and Washington, D.C., for filing false claims with the states' Medicaid programs.[109] The case arose under the False Claims Act with claims filed by Douglas Durand, a former TAP vice president of sales, and Joseph Gerstein, a doctor at Tufts University's HMO practice.[108] Durand, Gerstein, and Tufts shared $95 million of the settlement.[108]
There have since been various suits concerning leuprorelin use, none successful.[110][111] These lawsuits have focused on either the over-prescription of the drug or the lack of warnings about its potential side effects. Between 2010 and 2013, the FDA updated the Lupron drug label to include new safety information on the risk of thromboembolism, loss of bone density and convulsions.[112] The FDA then said that the benefits of leuprorelin outweighed its risks when used according to its approved labeling. From 2017 the FDA evaluated leuprorelin's connection to pain and discomfort in musculoskeletal and connective tissue.[113]
Humira
In March 2003, British company Cambridge Antibody Technology (CAT) stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" (Adalimumab) with Abbott Laboratories in the High Court of London. In December 2004, the judgment ruled for CAT.[114]
Abbott was required to pay CAT US$255 million in lieu of royalties the MRC, the Scripps Research Institute and Stratagene would have received on sales of Humira after December 2004. Some of this sum was to be passed to its partners in development, including US$191 million for the UK Medical Research Council (MRC), plus a further $7.5 million over five years from 2006 providing that Humira remained on the market.[115]
Operation Headwaters
In October 2003, Abbott Laboratories and two of its units agreed to pay a total of $600 million in the first combined civil settlement and criminal conviction for offering kickbacks to agents of "Operation Headwaters", an undercover investigation by the FBI.[116]
Depakote
On 2 October 2012, the company was charged with a $500 million fine and $198.5 million forfeiture for illegal marketing of Depakote for uses not approved by the FDA. The court also sentenced Abbott to a five-year term of probation and court supervision.[117] Shareholders then brought derivative suits against the company directors for breach of fiduciary duty.[118][119] Following Abbott's spinoff of its research-based pharmaceuticals business, it no longer owns the commercial rights and associated responsibilities for Humira and Depakote.[120]
Glucose monitors
In 2021, two of Abbott Laboratories' subsidiaries, Arriva Medical LLC and Alere Inc, had to pay $160m to resolve claims that it had fraudulently billed Medicare for glucose monitors. The US Department of Justice said that Arriva used free glucose monitors to induce patients to order more consumable supplies, then took kickbacks on the increased sales. The company was also accused of charging Medicare for glucose monitors given to patients who were ineligible, or even dead.[121]
Plant shutdown
In February 2022, Abbott recalled baby formulas from the market and shut down its Michigan plant after complaints of illness and death in infants caused by serious bacterial infections. Following Abbotts' meeting the initial requirement of the U.S. Food & Drug Administration, the facility reopened in June 2022.[122][123][124][125]
Deep Brain Stimulation device recall
In 2023, Abbott recalled its Proclaim and Infinity IPGs due to complaints from patients who could not exit MRI mode. The use of the affected IPGs may require surgery to remove the device and replace it with a new device.
There have been 186 reported incidents and 73 reported injuries. There have been no reports of death.[126] Noted by Gita Amar, a PR representative for Abbott Laboratories on this issue. "The company has communicated this action to physicians and regulatory bodies. No products need to be returned to the company or replaced."[127]
Necrotizing Enterocolitis (NEC) Lawsuit
On July 26, 2024, a jury ordered Abbott Laboratories to pay $495 million in the case of Margo Gill vs. Abbott Laboratories, comprising $95 million in compensatory damages and $400 million in punitive damages.[128] The lawsuit alleged that Abbott's infant formula for premature babies increased the risk of necrotizing enterocolitis (NEC), a gastrointestinal disease that can cause intestinal tissue death and can be life-threatening.
Sponsorship
In 2015 Abbott became the title sponsor of the World Marathon Majors.[129]
See also
- List of Illinois companies
- List of largest biomedical companies by market capitalization
- List of pharmaceutical companies
- Clara Abbott
- 2022 United States infant formula shortage
External links
References
- Bruce Japsen. After 20 Years, Abbott Labs CEO Miles White Has Successor in Mind Forbes, retrieved 10 September 2019^
- US SEC: Form 10-K Abbott Laboratories U.S. Securities and Exchange Commission, February 20, 2026^
- Abbott Laboratories Fortune^
- Abbott Laboratories Forbes^
- Abbott Laboratories Company History Funding Universe, retrieved 17 April 2013^
- Abbott in Pakistan | Abbott www.pk.abbott, retrieved 5 July 2023^
- RICHARD MOORE ROSS, 77, ABBOTT LABS EXECUTIVE Chicago Tribune, 11 December 1993, retrieved 2 June 2019^
- Ross Laboratories - Ohio History Central ohiohistorycentral.org, retrieved 2020-04-02^
- Marla Matzer Rose. Abbott Labs plans $62 million investment in Columbus The Columbus Dispatch, retrieved 2020-04-02^
- Welcome Sherri Blanchard, M.D., to Douglas Primary Care – Casper, WY Oil City News Oil City News, 2020-01-10, retrieved 2020-04-02^
- Lester Grinspoon, Peter Hedblom. The Speed Culture: Amphetamine Use and Abuse in America Harvard University Press, 1975^
- Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports Therapeutic Advances in Infectious Disease, August 2013^
- World Health Organization model list of essential medicines: 21st list 2019 World Health Organization, 2019^
- Abbott Closes Early On Knoll Acquisition Chicago Tribune, March 3, 2001^
- Company News; Chattem Buys Selsun Blue Shampoo Brand From Abbott The New York Times, March 6, 2002, retrieved 10 March 2024^
- Scott S. Smith. Miles White's Bold Moves Made Abbott Laboratories A Global Force Investor's Business Daily, January 11, 2018, retrieved 25 December 2018^
- Stacey Higginbotham. Abbott Labs to spin off unit American City Business Journals, January 25, 2004^
- Jillian Dabney. Pfizer's Hospira Deal: Catching Up a Year Later Market Realist, 2016-09-09^
- Jan Sandred. $1 billion medical deal / Abbott Labs to buy Therasense, maker of glucose monitors SFGATE, January 14, 2004, retrieved 10 March 2024^
- Barnaby Feder, Andrew Ross Sorkin. Boston Scientific, With Abbott's Help, Raises Bid for Guidant The New York Times, January 18, 2006, retrieved 10 March 2024^
- Barnaby Feder. Johnson & Johnson Sues Boston Scientific, Guidant and Abbott Laboratories Over Deal The New York Times, September 27, 2006, retrieved 10 March 2024^
- Scott S. Smith. Miles White's Bold Moves Made Abbott Laboratories A Global Force Investor's Business Daily, 11 January 2018, retrieved 25 December 2018^
- Rachel Layne, Elizabeth Lopatto. GE, Abbott End $8.13 Billion Diagnostic Sale Deal (Update2) 11 July 2007, retrieved 5 March 2017^
- Aesica Containment Facility Pharmaceutical Technology, November 7, 2013, retrieved 10 March 2024^
- Chris Tighe. Aesica seizes some bargain buys Financial Times, July 8, 2007, retrieved 10 March 2024^
- Paul Wilson. End of an era: Abbott retires Ross Products name The Columbus Dispatch, retrieved 2020-04-02^
- Johnson & Johnson completes $4.3B acquisition of Abbott Medical Optics in Santa Ana Orange County Register, 28 February 2017, retrieved 22 November 2019^
- Abbott Labs leasing space in UI research park The News Gazette, 2 May 2009, retrieved 22 November 2019^
- Abbott Completes Acquisition of Solvay Pharmaceuticals PR Newswire, February 26, 2010^
- Abbott Laboratories Feb 2010 Current Report, Form 8-K, Filing Date Feb 16, 2010 secdatabase.com, retrieved 27 December 2012^
- Abbott sets deal to buy Starlims Chicago Tribune, December 15, 2009, retrieved 10 March 2024^
- Abbott Completes Acquisition of STARLIMS Technologies PR Newswire, March 22, 2010^
- Peter Loftus, Rumman Ahmed. Abbott Labs to Buy Indian Business The Wall Street Journal, retrieved 26 September 2019^
- Drew Armstrong. AbbVie Rises on First Day of Trading After Abbott Spinoff Bloomberg News, 2 January 2013^
- Abbott Completes Separation of Research-Based Pharmaceuticals Business PR Newswire, January 2, 2013^
- More than splitting pills: Health care giant Abbott Laboratories ready to spin off AbbVie Chicago Tribune, December 30, 2012^
- Michael de La Merced, Bruce Japsen. Abbott Labs to Split into 2 Companies The New York Times, 19 October 2011^
- Jonathan D. Rockoff. Abbott to Split into Two Companies The Wall Street Journal, 20 October 2011^
- Abbott Labs 3Q net income rises; lays off 550 CNBC, October 17, 2012^
- Abbott to acquire CFR Pharmaceuticals Bloomberg News, 16 May 2014, retrieved 16 May 2014^
- Abbott Grows Branded Generics with $3.3B CFR Acquisition Genetic Engineering & Biotechnology News, 15 June 2014^
- Abbott Acquires Veropharm To Expand Presence in Russia Forbes, retrieved 17 October 2019^
- Abbott Laboratories (ABT) Key Developments Reuters.com^
- Abbott Completes Acquisition of Tendyne Holdings, Inc. PR Newswire, September 1, 2015^
- Abbott acquires Tendyne Holdings Jones Day, September 2015^
- FDA approves Abbott's Freestyle Libre glucose monitoring system Medical Device Network, 29 September 2017^
- Abbott to Acquire Alere for $5.8B Genetic Engineering & Biotechnology News, February 2016, retrieved 1 February 2016^
- Michelle Cortez. Abbott's $5.8 Billion Deal for Alere Is Device Sector's Latest Bloomberg L.P., 1 February 2016, retrieved 5 March 2017^
- Michelle Cortez. Abbott to Buy St. Jude Medical in Deal Valued at About $25 Billion Bloomberg L.P., 28 April 2016, retrieved 5 March 2017^
- Abbott-St. Jude Combination: Why It Makes Sense Bloomberg L.P., 28 April 2016, retrieved 5 March 2017^
- Abbott to Gain from Alere's Takeover Due for Oct 3 Closure GEN, retrieved 5 October 2017^
- Mail-Order Diabetic Testing Supplier and Parent Company Agree to Pay $160 Million to Resolve Alleged False Claims to Medicare United States Department of Justice, August 2, 2021^
- Embattled Arriva Medical closes GEN, retrieved 6 December 2017^
- Factbox: U.S. companies with exposure to Russia Reuters, 9 August 2018, retrieved 29 January 2019^
- With new FDA clearance, Abbott Freestyle Libre users can ditch handheld readers for an app Mobi Health News, November 2018, retrieved 17 October 2019^
- Abbott To Acquire Cephea Valve Technologies, Inc. BioSpace, retrieved 2 June 2019^
- Abbott's Tendyne™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation PR Newswire, January 30, 2020^
- FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits International Business Times, 19 March 2020^
- Grace Hauck. 'A game changer': FDA authorizes Abbott Labs' portable, 5-minute coronavirus test the size of a toaster USA Today, retrieved 2020-03-30^
- Steven Mufson. The scramble for the rapid coronavirus tests everybody wants The Washington Post, retrieved 2020-04-02^
- Matt Burns. Detroit to be first to deploy Abbott Labs' 5-minute COVID-19 test, mayor says TechCrunch, 2 April 2020, retrieved 2020-04-02^
- Chris Newmaker. Abbott receives FDA emergency use authorization for coronavirus test massdevice.com, 19 March 2020, retrieved 13 April 2021^
- Maria Rachal. Abbott enters coronavirus antibody testing fray medtechdive.com, 15 April 2020, retrieved 13 April 2021^
- Greg Slabodkin. Latest Abbott coronavirus antibody test receives FDA emergency use OK medtechdive.com, 11 May 2020, retrieved 13 April 2021^
- Garrett A. Perchetti, Gregory Pepper, Lasata Shrestha, Katrina LaTurner, Da Yae Kim, Meei-Li Huang, Keith R. Jerome, Alexander L. Greninger. Performance characteristics of the Abbott Alinity m SARS-CoV-2 assay Journal of Clinical Virology, July 2021^
- Annette Boyle. Two Abbott COVID-19 tests receive EUA bioworld.com, 12 May 2020, retrieved 13 April 2021^
- Chris Newmarker. Abbott wins EUA for COVID-19 test that runs off a card massdevice.com, 27 August 2020, retrieved 13 April 2021^
- This $5 rapid test is a potential game-changer in COVID-19 testing abc7.com, 27 August 2020^
- Sean Whooley. Abbott wins FDA EUA for COVID-19 IgM antibody test massdevice.com, 13 October 2020, retrieved 14 April 2021^
- Garrett A. Perchetti, Meei-Li Huang, Margaret G. Mills, Keith R. Jerome, Alexander L. Greninger. Analytical Sensitivity of the Abbott BinaxNOW COVID-19 Ag Card Journal of Clinical Microbiology, 2021-02-18^
- Tomi Kilgore. Abbott Labs' at-home, $25 rapid COVID-19 test gets EUA from FDA MarketWatch, 16 December 2020, retrieved 14 April 2021^
- Bruce Japsen. Abbott Profits Rise As Covid-19 Diagnostic Sales Eclipse 400 Million Tests Forbes, 27 January 2021, retrieved 14 April 2021^
- Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC 2 September 2021, retrieved 3 September 2021^
- Andrea Park. Abbott unveils Lingo line of sports biosensors based on diabetes monitoring tech FierceBiotech, Questex, January 6, 2022^
- Sarah Varney. Which Companies Aren't Exiting Russia? Big Pharma KFF Health News, 2022-03-10, retrieved 2025-02-20^
- Over 1,000 Companies Have Curtailed Operations in Russia—But Some Remain som.yale.edu, retrieved 2025-02-20^
- Nick Paul Taylor. Abbott's Libre 3 glucose monitor gets FDA clearance as CGM market intensifies MedTechDive, May 31, 2022, retrieved 29 December 2022^
- Andrea Park. Abbott proclaims FDA approval of neurostimulator to treat pain in 6 areas at once FierceBiotech, Questex, August 23, 2022^
- Nick Paul Taylor. Abbott lands FDA emergency authorization for first commercial monkeypox test MedTechDive, October 10, 2022, retrieved 29 December 2022^
- Abbott Completes Acquisition of Cardiovascular Systems, Inc. PR Newswire, April 27, 2023^
- Abbott Completes Acquisition of Bigfoot Biomedical PR Newswire, September 22, 2023^
- Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes 5 September 2023, retrieved 7 September 2023^
- Peter Loftus and Nicholas G. Miller. Abbott to Acquire Exact Sciences for $21 Billion The Wall Street Journal, 2025-11-20, retrieved 2025-11-20^
- Dana Elfin. Abbott names Robert Ford new CEO, ending Miles White's 21-year tenure in March Medtechdive, retrieved 19 March 2020^
- Abbott CEO Miles White to step down in March retrieved April 8, 2020^
- Andrea Park. Abbott elects CEO Ford chairman of the board as predecessor White retires after 40 years FierceBiotech, Questex, December 13, 2021^
- World's Most Admired Companies Fortune^
- Fortune's Blue Ribbon Companies 2021 Fortune^
- Change the World Fortune^
- Jay Woodruff. The 10 most innovative companies in sports in 2022 Fast Company, March 8, 2022^
- These innovative projects are changing the health industry Fast Company, May 3, 2022, retrieved 13 February 2023^
- Sean Whooley. Abbott FreeStyle Libre named 'best medical technology' in last 50 years by Galien Foundation MassDevice, 28 October 2022, retrieved 5 July 2023^
- 2022 100 BEST COMPANIES WINNERS Seramount^
- 2022 TOP COMPANIES FOR EXECUTIVE WOMEN WINNERS Seramount^
- Abbott Working Mother, retrieved 2020-04-02^
- 2020's Top Employers: Rapid response to COVID-19, diversity, and innovation Science Magazine, retrieved 26 October 2021^
- 2022 TOP 50 COMPANIES FOR DIVERSITY DiversityInc, 7 July 2023^
- Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI) Bloomberg, 15 November 2021^
- Joseph (Joe) Smith, Anita Varga, Karsten E. Schober. Comparison of two commercially available immunoassays for the measurement of bovine cardiac troponin I in cattle with induced myocardial injury Frontiers in Veterinary Science, 2020^
- Betsy Morris. Which Covid-19 Test Should You Get, Based on Your Needs The Wall Street Journal, August 25, 2021, retrieved 30 August 2021^
- Freestyle libre 3 Sensor Cgm Monitors, retrieved 2022-08-19^
- Alex Knapp. FDA Gives The Okay For Abbott’s New Minimally Invasive Pacemaker Forbes, July 5, 2023, retrieved January 1, 2026^
- Peter Bodkin. How the IDA's top client used Ireland to siphon billions offshore tax-free TheJournal.ie, 19 March 2019^
- Damian Paletta, Kate Linebaugh. Dublin Moves to Block Controversial Tax Gambit The Wall Street Journal, 15 October 2013^
- Pat Leahy. Pharma giant Abbott using Irish 'single-malt' scheme to avoid tax on profits The Irish Times, 15 September 2021, retrieved 16 September 2021^
- Cliff Taylor. How Abbott Labs devised its formula for 'single Malt' taxation The Irish Times, 15 September 2021^
- Fred Charatan. Drug companies defrauded Medicare of millions BMJ: British Medical Journal, 2001-10-13^
- Melody Petersen. 2 Drug Makers to Pay $875 Million to Settle Fraud Case The New York Times, 2001-10-04, retrieved 2022-01-24^
- #513: 10-03-01 TAP PHARMACEUTICAL PRODUCTS INC. AND SEVEN OTHERS CHARGED WITH HEALTH CARE CRIMES COMPANY AGREES TO PAY $875 MILLION TO SETTLE CHARGES www.justice.gov, retrieved 2022-01-24^
- What You Should Know About Lupron Class Action Lawsuit Law Answer, 2021-05-08, retrieved 2022-02-28^
- Abbott, AbbVie Defeat Long-Running Lupron Bone, Joint Suit (1) news.bloomberglaw.com, 29 September 2021, retrieved 2022-02-28^
- More women come forward with complaints about Lupron side effects KTNV, 2019-02-12, retrieved 2022-02-28^
- With updates; last update 6 January 2023. January - March 2017 FDA, 3 January 2023, retrieved 28 February 2022^
- Cambridge Antibody Wins Lawsuit Against Abbott Labs (Update5) – Bloomberg Bloomberg News, 16 July 2023, retrieved 5 March 2017^
- MRC to receive over USD200m LifeArc, 2005-10-26, retrieved 2022-02-28^
- #613: 11-10-03 JUSTICE DEPT. CIVIL FRAUD RECOVERIES TOTAL $2.1 BILLION FOR FY 2003 FALSE CLAIMS ACT RECOVERIES EXCEED $12 BILLION SINCE 1986 www.justice.gov, retrieved 2022-01-24^
- Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil Investigations of Off-label Promotion of Depakote, Press Release, United States Department of Justice Office of Public Affairs, 7 May 2012. Retrieved 17 August 2014.^
- U.S. ex rel. McCoyd v. Abbott Laboratories, 1:07-cv-00081 (W.D. Va.); U.S. ex rel. Mulcahy v. Abbott Laboratories, 1:08-cv-0054 (W.D. Va.); U.S. ex rel. Dietzler v. Abbott Laboratories, 1:09-cv-00051 (W.D. Va.); U.S. ex rel. Spetter v. Abbott Laboratories, 1:10-cv-00006 (W.D. Va.).^
- Abbott, Shareholders Agree To Settle Depakote Marketing Suit - Law360 www.law360.com, retrieved 5 July 2023^
- Ransdell Pierson Krauskopf. Abbott ultra-bullish on Humira despite spinoff plan Reuters, 21 October 2011, retrieved 22 November 2019^
- Jonathan Stempel. Abbott Labs to pay $160 mln over kickbacks, false diabetes claims to Medicare Reuters, 2021-08-02, retrieved 2022-01-24^
- Explainer: What happened with Abbott baby formula that worsened a U.S. shortage? Reuters, 2022-05-17, retrieved 2022-06-04^
- Ahmed Aboulenein, Susan Heavey. U.S. FDA says Abbott baby formula plant on track to reopen in 1-2 weeks Reuters, 2022-05-19, retrieved 2022-06-04^
- Baby formula shortage could ease as Abbott reopens Michigan plant Reuters, 2022-06-04, retrieved 2022-06-04^
- Abbott baby formula aftermath: One dead child and another with brain damage so bad she has constant seizures and crying bouts Fortune Well, retrieved 2024-03-18^
- Center for Devices and Radiological Health. Abbott Medical Recalls Proclaim and Infinity IPGs for Inability to Exit Magnetic Resonance Imaging (MRI) Mode FDA, 2023-09-13, retrieved 22 September 2023^
- Abbott Recalls Certain Proclaim, Infinity Neurostimulation Devices 2023-09-13, retrieved 2023-09-22^
- TorHoerman Law Obtains $495 Million NEC Verdict as Lead Counsel in Infant Formula NEC Trial Against Abbott Laboratories TorHoerman Law, LLC, 2025-04-03, retrieved 2025-04-03^
- ABBOTT CELEBRATES THE POWER OF HEALTH AND ACHIEVEMENT AS FIRST-EVER TITLE SPONSOR OF WORLD MARATHON MAJORS World Marathon Majors, retrieved 10 November 2015^